Preoperative Immunonutrition and Elective Colorectal Resection Outcomes
Overview
Authors
Affiliations
Background: Randomized controlled trials demonstrate the efficacy of arginine-enriched nutritional supplements (immunonutrition) in reducing complications after surgery. The effectiveness of preoperative immunonutrition has not been evaluated in a community setting.
Objective: This study aims to determine whether immunonutrition before elective colorectal surgery improves outcomes in the community at large.
Design: This is a prospective cohort study with a propensity score-matched comparative effectiveness evaluation.
Settings: This study was conducted in Washington State hospitals in the Surgical Care Outcomes Assessment Program from 2012 to 2015.
Patients: Adults undergoing elective colorectal surgery were selected.
Interventions: Surgeons used a preoperative checklist that recommended that patients take oral immunonutrition (237 mL, 3 times daily) for 5 days before elective colorectal resection.
Main Outcome Measures: Serious adverse events (infection, anastomotic leak, reoperation, and death) and prolonged length of stay were the primary outcomes measured.
Results: Three thousand three hundred seventy-five patients (mean age 59.9 ± 15.2 years, 56% female) underwent elective colorectal surgery. Patients receiving immunonutrition more commonly were in a higher ASA class (III-V, 44% vs 38%; p = 0.01) or required an ostomy (18% vs 14%; p = 0.02). The rate of serious adverse events was 6.8% vs 8.3% (p = 0.25) and the rate of prolonged length of stay was 13.8% vs 17.3% (p = 0.04) in those who did and did not receive immunonutrition. After propensity score matching, covariates were similar among 960 patients. Although differences in serious adverse events were nonsignificant (relative risk, 0.76; 95% CI, 0.49-1.16), prolonged length of stay (relative risk, 0.77; 95% CI, 0.58-1.01 p = 0.05) was lower in those receiving immunonutrition.
Limitations: Patient compliance with the intervention was not measured. Residual confounding, including surgeon-level heterogeneity, may influence estimates of the effect of immunonutrition.
Conclusions: Reductions in prolonged length of stay, likely related to fewer complications, support the use of immunonutrition in quality improvement initiatives related to elective colorectal surgery. This population-based study supports previous trials of immunonutrition, but shows a lower magnitude of benefit, perhaps related to compliance or a lower rate of adverse events, highlighting the value of community-based assessments of comparative effectiveness.
The impact of immunonutrition on pancreaticoduodenectomy outcomes.
Wang X, Littau M, Fahmy J, Kisch S, Varsanik M, OHara A Surg Pract Sci. 2025; 10():100106.
PMID: 39845588 PMC: 11749982. DOI: 10.1016/j.sipas.2022.100106.
Koo T, Leong X, Zakaria A Malays J Med Sci. 2025; 31(6):65-76.
PMID: 39830099 PMC: 11740823. DOI: 10.21315/mjms2024.31.6.6.
Current research and future prospects of immunonutrition in gastrointestinal malignancies.
Ma X, Pei B, Wu N, Wang C, Yu Y, Yang W Front Immunol. 2024; 15:1420415.
PMID: 39308867 PMC: 11412812. DOI: 10.3389/fimmu.2024.1420415.
Yue T, Xiong K, Deng J, Hu W, Tan T, Li S Front Nutr. 2022; 9:945590.
PMID: 36479293 PMC: 9719975. DOI: 10.3389/fnut.2022.945590.
Benavides-Buleje J, Fernandez-Fernandez P, Ruiz-Ucar E, Solana-Bueno A, Parra-Banos P, Martinez-Torres B Nutrients. 2022; 14(15).
PMID: 35893914 PMC: 9331223. DOI: 10.3390/nu14153062.